Lupin’s 10 mg Amifampridine Tablets Gain Tentative USFDA Approval for LEMS
Lupin Limited, a global pharmaceutical leader based in Mumbai, India, has received tentative approval from the United States Food and Drug Administration (USFDA) for its Amifampridine Tablets, 10 mg. This approval marks a significant advancement in the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. “Lupin’s 10 mg Amifampridine Tablets Gain Tentative USFDA […]
Lupin’s 10 mg Amifampridine Tablets Gain Tentative USFDA Approval for LEMS Read More »










